Background Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by mutations of the SMN1 gene. Based on severity, three forms of SMA are recognised (types I–III). All patients usually have 2–4 copies of a highly homologous gene (SMN2) which produces insufficient levels of functional survival motor neuron (SMN) protein. Recently, evidence has been provided that SMN2 expression can be enhanced in vitro by salbutamol, a β2-adrenergic agonist. This compound has also been shown to improve motor function of SMA patients in two different pilot trials.
Aim To evaluate the in vivo molecular efficacy of salbutamol in SMA patients.
Methods Twelve type II–III patients took salbutamol orally for 6 months. SMN2 full length transcript levels were determined in peripheral blood leucocytes by absolute real-time PCR, at baseline and after 3 and 6 months of treatment.
Results A significant and constant increase in SMN2 full length transcript levels was detected; the response was directly proportional to SMN2 gene copy number.
Conclusions The data strongly support salbutamol as a candidate for treating SMA, and suggest that SMN2 copy number may predict the molecular response to treatment and may be a useful randomisation parameter in a double blind placebo controlled clinical trial design.
- Spinal muscular atrophy
- pilot trial
- molecular genetics
- motor neurone disease
- neuromuscular disease
Statistics from Altmetric.com
Funding Other funders: Telethon Italia Grant GGP07035.
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Catholic University Rome Italy.
Provenance and peer review Not commissioned; externally peer reviewed.